Phase 1 will be ambispective, multi-site, single arm study in age-related cataract patients with regular astigmatism, who were bilaterally treated with the LAL+ IOLs

Phase 2 will be a prospective, randomized, unmasked, comparative, multi-site study with 90 days of follow up. Subjects will be randomized in a 1:1 manner to LAL+ or Clareon VIvity Toric IOLs.

Inclusion Criteria:

• Adult (≥45) subjects who are astigmatic and require bilateral, routine small-incision, surgery for age-related cataracts with femtosecond laser;
• All subjects will be required to be targeted for refractive emmetropia (plano or first minus closest to plano);
• Subjects will have an expected monocular BCDVA outcomes of 20/25 or better in the opinion of the investigator;
• Subjects will have regular corneal astigmatism (1.00 to 2.00 D), which can be corrected with a toric power IOL of T3-T5;
• Subjects will be required to have a dilated pupil diameter of 7 mm or greater in both eyes;

Exclusion Criteria:

• Moderate-severe corneal pathology;

  • Irregular astigmatism;
  • Subject desire monovision correction;
  • Preexisting macular disease or other retinal degenerative diseases that is expected to cause future vision loss;
  • History of glaucoma;
  • Severe dry eye disease;
  • History of uveitis;
  • History of ocular herpes simplex virus;
  • History of nystagmus;
  • Zonular laxity or dehiscence;
  • History psueudoexfoliation;
  • History of corneal refractive and intraocular surgery or requiring any other planned ocular surgical procedures;
  • Currently taking systemic medication that may increase sensitivity to UV light or that may cause toxicity to the retina;
  • Pregnant or breastfeeding.